Tight coupling of the activity of osteoblasts to build bone and osteoclasts to resorb bone is necessary to maintain the local biomechanical properties of bone. Moreover, this coupling ac tivity limits the effectiveness of current therapies to treat osteoporosis, as antiresorptives targeting osteoclasts also induce a decrease in osteoblast activity, and the ability of the PTH agonist teraparatide to promote bone formation is par tially counterbalanced by increased osteoclast re sorptive activity (Sims and Gooi, 2008) . Thus, understanding the basis of osteoclast/osteoblast Deletion of CHMP5 augments RANKL sensitivity to osteoclast differentiation To examine the role of CHMP5 in osteoclast develop ment, BM monocytes (BMMs) isolated from Chmp5 fl/fl and Chmp5 Ctsk mice were treated with MCSF and RANKL in vitro. During osteoclast differentiation CHMP5 expression was markedly increased in Chmp5 fl/fl osteoclasts, whereas Chmp5 Ctsk osteoclasts fail to induce CHMP5 expression (Fig. 2 A) . Osteoclast differentiation and sensitivity to RANKL were coupling is central to designing improved approaches to treat diseases of low bone mass such as osteoporosis.
Paget's disease of bone (PDB) affects 1-5% of adults over the age of 55 and is characterized by a wave of increased lytic osteoclast activity coupled with exuberant osteoblast activity, ultimately resulting in bone thickening, sclerosis, and expan sion (van Staa et al., 2002; Daroszewska and Ralston, 2006; Ralston et al., 2008) . These increases in osteoblast function and bone formation are believed to be driven by alterations in os teoclasts by as yet unknown coupling mechanisms (Roodman and Windle, 2005; Galson and Roodman, 2014) . Notably, rare forms of PDBlike syndromes such as familial expansile osteoly sis, early onset familial PBD, expansile skeletal hyperphospha tasia, juvenile PDB (JPD; familial idiopathic hyperphosphatasia), and inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) concur rently affect many bones (Daroszewska and Ralston, 2006) . Risk factors influencing development of classical and rare forms of PDB include genetic variants in CSF1, TNFRSF11A, TNFRSF11B, SQSTM1/p62, VCP/p97, and OPTN, which are closely linked to the NFB pathway downstream of receptor activator of NFB (RANK), a cytokine receptor that has an essential function to drive osteoclast differentiation, and the proteasomal degradation pathway (Albagha et al., 2010 (Albagha et al., , 2011 . Additionally, environmental stressors such as chronic measles virus (MV) infection have been implicated in PDB development (Kurihara et al., 2011) . However, despite these advances, the molecular pathobiology of both PDB develop ment and the exaggerated coupling between osteoclast and osteoblast activities is unclear.
Previously, in an attempt to identify novel regulators of the NFB pathway, we identified charged multivesicular body protein 5 (CHMP5) as copurifying with the cytosolic NFB-IB complex from rabbit lung tissue extracts (Shim et al., 2006) . CHMP5 is a mammalian orthologue of the yeast VPS60/ MOS10 and is essential for late endosomal trafficking and mul tivesicular body formation as a component of the endosomal sorting complex required for transport (ESCRT) machinery (Babst et al., 2002; Köhler, 2003; Shim et al., 2006) . The ESCRT machinery in turn has been demonstrated to be involved in an increasing number of diverse cellular procedures beyond tradi tional endocytic trafficking such as autophagy, cytokinesis, cell polarity, migration, and viral budding (Raiborg and Stenmark, 2009; Rusten et al., 2012) . To study the contribution of CHMP5 to NFB signaling in vivo, Chmp5 / mice were generated; however, these mice displayed embryonic lethality associated with defective lysosomal biogenesis (Shim et al., 2006) . This finding largely precluded the study of the physiological contri bution of CHMP5 to NFB signaling in vivo. Given the im portance of NFB signaling in osteoclast biology (Jimi et al., 2004; Novack, 2011) , we investigated whether CHMP5 regu lates NFB signaling in this context using a conditional floxed allele of Chmp5.
Here, we demonstrate that CHMP5 dampens RANK mediated activation of NFB in osteoclasts, in turn increas ing the threshold of stimulation required for osteoclast promote osteoblast differentiation in vitro via secreted cou pling factors (Fig. 4 C) .
Signaling between EphB4 on osteoblasts and its primary ligand ephrinB2 on osteoclasts stimulates osteoblast differen tiation (Zhao et al., 2006) . To determine the contribution of the EphrinB2-EphB4 pathway to the enhanced osteoblast coupling seen in Chmp5 Ctsk osteoclasts, EphB4Fc fusion pro tein was added to osteoclast/osteoblast cocultures to suppress EphrinB2-EphB4 signaling (Fig. 4, D and E) . Treatment with EphB4Fc decreased osteoblast mineralization activity, revers ing the effect of Chmp5 Ctsk osteoclasts to promote osteoblast differentiation. Thus, the EphrinB2-EphB4 pathway is likely to be one important contributor to the enhanced osteoblast coupling activity of Chmp5 Ctsk osteoclasts, though other path ways are likely to contribute as well.
Next, we examined the in vivo expression levels of the coupling factors known to be important for bone remodeling by RNA sequencing of marrowflushed tibias. As shown in Fig. 4 F, Chmp5 Ctsk long bones showed elevated levels of both osteogenic factors such as Tgbf1 (Tang et al., 2009) , Igf1 (Xian et al., 2012) , and Lif (Cornish et al., 1997) and an os teoclastogenic factor Csf1 (Wei et al., 2006) , whereas expres sion of other genes, including Cxcl12, Fgf2, Bmp2, and Bmp6 in Chmp5 Ctsk long bones was comparable to levels in Chmp5 fl/fl bones. An elevated Rankl/Opg ratio was also observed in Chmp5 Ctsk long bones, suggesting an increase in bone remod eling activity (Fig. 4 G) . As reported in BMSCs and osteo blasts isolated from PDB patients (Naot et al., 2007) , Chmp5 Ctsk long bones show distinct patterns of expression of two WNT signaling antagonists, an increased expression of Dickkopf1 (Dkk1) and a decreased expression of Sclerostin (Sost; Fig. 4 H) . Collectively, Chmp5 deletion in osteoclasts enhances tran scriptional programs corresponding to osteoclast differentiation/ activity and also augments production of osteoclast-osteoblast coupling factors.
Osteoblast activity is highly increased in Chmp5 Ctsk mice
To examine whether the elevated levels of the coupling fac tors observed in Chmp5 Ctsk osteoclasts correspond to increased osteoblast activity in vivo, dynamic histomorphometry analy sis was conducted. As seen in Fig. 5 (A-B) , bone formation rate, mineral apposition rate, and numbers of osteoblasts are markedly increased in periosteal Pagetic lesions. Likewise, in situ hybridization demonstrated increased numbers of mature osteoblasts expressing type 1 collagen 1 (Col1) and osteo calcin (Ocn) in these bone lesions (Fig. 5 C) . Consistent with a previous study showing that mature osteoblasts express high levels of vascular endothelial growth factors (VEGFs) and with clinical observations that Pagetoid lesions are hypervas cular to the point of occasionally causing highoutput heart failure in severe polyostotic cases (Chakravorty, 1978; Zajac and Phillips, 1985; Deckers et al., 2000) , these bone lesions are hypervascular and display elevated levels of VEGF expres sion (Fig. 5, D-F) . Additionally, the serum levels of the bone turnover markers ALP, CTX, and Nterminal propeptide of type 1 procollagen (P1NP) were all significantly increased in dramatically increased in Chmp5 Ctsk BMMs, as indicated by an increase in tartrateresistant acid phosphatase (TRAP) staining and activity (Fig. 2 , B-D) and osteoclast marker gene expression (Fig. 3, A and B) . Likewise, Chmp5 Ctsk osteoclasts displaced markedly increased bone resorptive activity with a 2-3 fold increase in the number and area of resorption pits and in the liberation of type I collagen Cterminal telopep tide (CTX; Fig. 2 E) . This increase in resorptive activity likely reflected both increased differentiation and proliferation, as carboxyfluorescein succinimidyl ester (CFSE) labeling dem onstrated increased proliferation of Chmp5 Ctsk BMMs under osteoclast differentiation conditions (unpublished data). Simi lar to observations made in human PDB patients (Rebel et al., 1974) , Chmp5 Ctsk osteoclasts were larger and contained more nuclei than Chmp5 fl/fl osteoclasts (Fig. 2 F) .
Osteoclast differentiation is accompanied by cytoskeletal reorganization necessary to orient the resorptive machinery toward the bone surface and to seal around the resorption pit (Teitelbaum and Ross, 2003) where the Src protooncogenes serve as key regulators of this process (Soriano et al., 1991; Zou et al., 2007; Izawa et al., 2012) . Intriguingly, Chmp5 Ctsk osteo clasts show elevated levels and activation of Src and increases in the activation of the downstream effectors Syk and active GTP bound Rac1 (Fig. 2, G-I ). In keeping with these observations, actin ring formation was enhanced in Chmp5 Ctsk osteoclasts (Fig. 2 J) . Thus, CHMP5 coordinately regulates several aspects of osteoclast differentiation necessary for resorptive activity.
Deletion of CHMP5 augments production of osteoblast/osteoclast coupling factors in osteoclasts To determine how CHMP5 regulates gene expression in os teoclasts, we performed RNA sequencing analysis of Chmp5 fl/fl and Chmp5 Ctsk osteoclasts. As expected, geneset enrichment analysis (GSEA) showed an enrichment of genes associated with osteoclast differentiation and fusion in Chmp5 Ctsk osteo clasts, and the increase in gene expression was confirmed by RTPCR analysis (Fig. 3, A and B) . Expression of IL6, a sig nature gene of Pagetic osteoclasts (Hoyland et al., 1994; Roodman et al., 1992; Roodman and Windle, 2005) was also increased by 3-4fold in Chmp5 Ctsk osteoclasts (Fig. 3 C) . In triguingly, genes associated with Ephrin Bmediated reverse signaling were enriched in Chmp5 Ctsk osteoclasts (Fig. 3 D ; Zhao et al., 2006) . Additionally, Chmp5 Ctsk osteoclasts show an increase in expression of several clastokines, secreted osteoclast derived coupling factors that promote osteoblast activity, in cluding Efnb2 (Zhao et al., 2006) , Sphk1 (Ryu et al., 2006) , Cthrc1 (Takeshita et al., 2013) , Wnt10b (Ota et al., 2013) , and Bmp6 (Teti, 2013; Fig. 3 E) . The high expression of several clastokines in Chmp5 Ctsk osteoclasts prompted us to examine the ability of Chmp5 Ctsk osteoclasts to promote osteoblast dif ferentiation. Coculture with Chmp5 Ctsk osteoclasts increased mineralization and ALP activity to a greater extent than that seen with corresponding WT controls (Fig. 4, A and B) . As the same effects were observed with conditioned medium from Chmp5 Ctsk osteoclasts, CHMP5deficient osteoclasts also (Fig. 6 ). Though Rank-Het mice do not display detect able bone phenotypes at baseline (Dougall et al., 1999) , CKO;Rank-Het mice displayed a substantial reversal of the PDBlike bone phenotypes in Chmp5 Ctsk mice, including low trabecular bone mass, bone expansion, and the existence of Pagetoid lesions (Fig. 6, A-E) . Additionally, elevated num bers of osteoclasts and high serum levels of bone turnover markers observed in the CKO mice were largely normalized Chmp5 Ctsk mice, consistent with a high bone turnover state (Fig. 5 G) . Given that CHMP5 expression and osteoblast dif ferentiation and activity were all normal in the cultured os teoblasts from Chmp5 Ctsk bone marrow stromal cells (BMSCs; unpublished data), this strongly suggests that the high bone turnover state is intrinsic to the function of CHMP5 in os teoclasts. Collectively, Chmp5 Ctsk mice demonstrate a high bone turnover state complete with early onset and polyos totic de novo formation of expansile Pagetoid lesions on periosteal surfaces. In this respect, the phenotype of Chmp5 Ctsk mice best resembles the severe polyostotic forms of Paget's seen in human JPD or other heritable PDBlike disorders such as familial expansile osteolysis (Bakwin and Eiger, 1956) as opposed to typical sporadic PDB that typically manifests as focal lesions in patients over age 50 (Daroszewska and Ralston, 2006; Galson and Roodman, 2014) . Expression of the genes involved with osteoclast differentiation and fusion is highly increased in Chmp5 Ctsk osteoclast culture. RT-PCR analysis was performed with total RNAs isolated from cultured Chmp5 fl/fl and Chmp5 Ctsk osteoclasts (n = 3 mice/group). (C and E) Expression of IL-6 (C) and known clastokines (E) in cultured Chmp5 fl/fl and Chmp5 Ctsk osteoclasts was measured by RT-PCR analysis (n = 3 mice/group). Data in B, C, and E represent n = 3 independent experiments. All error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Bonferroni-corrected two-tailed Student's t tests.
can potentially reduce their rate of bone turnover and prevent the development of skeletal deformity (Cundy et al., 2004 (Cundy et al., , 2005 Polyzos et al., 2014) . Thus, assessment of the response of Chmp5 Ctsk mice to antiresorptives is important to determine the relevance of the model to human PDBspectrum disor ders and also to mechanistically evaluate the contribution of RANKL signaling. Chmp5 fl/fl or Chmp5 Ctsk mice were treated with PBS, alendronate, zolendronate, or recombi nant osteoprotegerinFc fusion (OPGFc) weekly from 2-6 wk of age (Fig. 7) . The low bone mass, bone expansion, and elevated by Rank haploinsufficiency (Fig. 6 , D-F). Thus, a partial re duction in RANK expression levels imparted by Rank haplo insufficiency can reverse the PDBlike bone phenotype of Chmp5 Ctsk mice, arguing that the ability of CHMP5 deletion to increase osteoclast responsiveness to RANK stimulation is central to the pathogenesis of the PDBlike skeletal disorder in Chmp5 Ctsk mice.
Previous case reports have suggested that treatment of pa tients with JPD with antiresorptives such as bisphosphonates, recombinant OPG, or the antiRANKL antibody Denosumab (WT-OC) and Chmp5 Ctsk (CKO-OC) BMMs in basal (BM) or osteoblast differentiation medium (OBM) in the presence of M-CSF and RANKL, and then stained with alizarin red (A); alizarin red was then measured by colorimetric analysis for mineralization activity (B). **, P < 0.01 by a Bonferronicorrected two-tailed Student's t test. (C) Primary calvarial osteoblasts were cultured under OBM in the presence of conditioned medium (CM) collected from Chmp5 fl/fl (WT) and Chmp5 Ctsk (CKO) osteoclasts, and alkaline phosphatase activity (ALP) was measured to assess osteoblast differentiation. **, P < 0.01 by a Bonferroni-corrected two-tailed Student's t test. (D and E) Various concentrations of mouse IgG-Fc or EphB4-Fc fusion proteins were added to the co-culture of osteoblasts and Chmp5 fl/fl or Chmp5 Ctsk BMMs in osteoblast differentiation medium containing M-CSF and RANKL. Mineralization activity was assessed by alizarin red staining. *, P < 0.05 by a Bonferroni-corrected two-tailed Student's t test. (F-H) Total RNA was isolated from 6-wk-old male Chmp5 fl/fl and Chmp5 Ctsk tibias (n = 6 mice/group) for RT-PCR analysis. Data in A-C and E-H represent n = 3 independent experiments. All error bars indicate SEM. **, P < 0.01; ***, P < 0.001 by a Bonferroni-corrected two-tailed Student's t test. Bar: (A) 5 mm. mice than either alendronate or zolendrate. Coupled with the finding that Rank haploinsufficiency rescues the Chmp5 Ctsk phenotype, this result confirms that the development of the PDBlike phenotype in Chmp5 Ctsk mice is highly dependent on the relative levels of RANK signaling and osteoclast differ entiation/activity in vivo.
serum levels of bone turnover markers observed in Chmp5 Ctsk mice were reversed by treatment with antiresorptive agents. Osteoclast differentiation was completely abolished by OPGFc treatment, whereas treatment with bisphosphonates blocked bone resorption activity ( Number of capillaries in cross section of cortical bones (n = 10 fields/slide from 5 randomized mice/group). (F) Cortical bones of 12-wk-old male Chmp5 fl/fl mice were used as WT control. **, P < 0.01 by a Bonferroni-corrected two-tailed Student's t test. (E) Total RNA was isolated from 6-wk-old male Chmp5 fl/fl and Chmp5 Ctsk tibias, and Vegf-A expression was measured by RT-PCR (n = 6 mice/group). *, P < 0.05 by a Bonferroni-corrected two-tailed Student's t test. (G) Serum levels of CTX, P1NP, and ALP in 12-wk-old male Chmp5 fl/fl and Chmp5 Ctsk mice (n = 7 mice/group). **, P < 0.01 by a Bonferroni-corrected two-tailed Student's t test. Bars: (C and D) 50 µm. (B and C; n = 7 mice/group). Red arrows indicate maximal femoral diameter. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a Bonferroni-corrected two-tailed Student's t test. (D and E) Femurs of the indicated mice were stained for histological analysis, including hematoxylin and eosin and TRAP staining, and the images are compilation/mosaics (E). TRAP-positive osteoclasts were counted in trabecular bones of WT and CKO;Rank het mice and Pagetoid lesions in CKO mice (n = 7 mice/group; D). ***, P < 0.001 by a Bonferroni-corrected two-tailed Student's t test. (F) Serum levels of CTX, P1NP, and ALP in 12-wk-old male WT, Rank het, CKO, and CKO;Rank het mice (n = 7 mice/group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 by a Bonferroni-corrected two-tailed Student's t test. All error bars indicate SEM. Bars: (E, top and middle) 100 µm; (E, bottom) 25 µm. IB were not observed, indicating selective interactions be tween CHMP5 and NFB and IB isoforms (unpublished data) . In this context, luciferase assay with a NFB respon sive reporter showed that RANKLinduced NFB activa tion was significantly inhibited by CHMP5 overexpression, whereas CHMP5 deficiency enhanced RANKLinduced ac tivation of NFB (Fig. 8 D) . Accordingly, Chmp5 Ctsk osteo clasts displayed an increase in NFB DNAbinding activity and a decrease in IB levels (Fig. 8, E and F) . Blocking this NFB activity ablates enhanced activity of TRAP in Chmp5 Ctsk osteoclasts, suggesting that aberrant NFB signaling is re sponsible for the phenotypes observed in Chmp5 Ctsk osteoclasts (Fig. 8 G) . Furthermore, phosphorylation levels of IKK/ CHMP5 suppresses RANK-mediated NF-B activation in osteoclasts We previously reported that CHMP5 functions as a negative regulator of NFB signaling downstream of proinflamma tory cytokines, though the mechanism of this effect was un clear (Shim et al., 2006) . Sizeexclusion chromatography of the preosteoclast line Raw 264.7 showed that endogenous CHMP5 cofractionated with a subset of NFB RelA and IB in an 550kD complex (Fig. 8 A) . Immunoprecipita tion analysis confirmed that both endogenous and overex pressed CHMP5 interacts with RelA and IB in an osteoclast line and HEK293 cells, respectively (Fig. 8, B and C) . How ever, the interactions with NFB p50, NFB p100, and (D) RAW264.7 cells were transfected with Chmp5 in a dose-dependent manner along with PBII-luc and Renilla and stimulated with 50 ng/ml of RANKL (top) or RAW264.7 cells expressing control, or Chmp5 shRNA were treated with different concentrations of RANKL (bottom). Relative luciferase activity was normalized to Renilla. *, P < 0.05; ***, P < 0.0001 by a Bonferroni-corrected two-tailed Student's t test. (E-G) Chmp5 fl/fl and Chmp5 Ctsk BMMs were cultured in the presence of M-CSF and RANKL, and after 3 d total cell lysates were used for an NF-B DNA-binding assay (E) or immunoblotted with the indicated antibodies (F). Alternatively, BMMs were infected by lentiviruses expressing vector or the super repressor, HA-IB-RR, and osteoclast differentiation was measured by TRAP activity (G). **, P < 0.01; ***, P < 0.0001 by a Bonferronicorrected two-tailed Student's t test.
CHMP5, CHMP5 is unlikely to suppress the IB ubiqui tination or directly possess deubiquitinating enzyme activity (unpublished data). CHMP5 overexpression did not inhibit RANKLinduced NFB activation in the absence of USP15, indicating that CHMP5 requires USP15 to suppress NFB signaling downstream of RANKL (Fig. 9 F) . In this respect, USP15 overexpression inhibited RANKLinduced NFB activation (Fig. 9 G) and USP15 knockdown increased sensi tivity of RANKL to osteoclast differentiation (Fig. 9 H) . Col lectively, these data suggest that the CHMP5-USP15 complex suppresses RANKmediated NFB activation via IB sta bilization in osteoclasts, in which mechanism it prevents pro teasomal degradation of IB leading to the retention of NFB in an inactive cytosolic complex.
CHMP5 mediates deubiquitination of the VCP/p97 complex via USP15
VCP/p97 is a type II AAAATPase that regulates unfolding of proteins as a ubiquitinselective chaperone, and genetic variants in VCP cause inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD; Rape et al., 2001; Watts et al., 2004) . As it has also been suggested that VCP/p97 regulates ubiquitinmediated proteasomal degradation of IB (Dai et al., 1998) , we specu lated that VCP/p97 may cooperate with CHMP5 and USP15 to regulate IB degradation. To confirm the observation that the CHMP5 complex in osteoclasts contains the deubiq uitinating enzyme USP15 and VCP/p97 (Fig. 8, A and I) , the physical interactions between CHMP5, USP15, and VCP/ p97 were studied using cellfree immunoprecipitation analysis (Fig. 10 A) . Intriguingly, CHMP5 interacts directly with both USP15 and VCP/p97, whereas there was no direct inter action between USP15 and VCP/p97. Likewise, in osteoclasts the interaction of USP15 with VCP/p97 was markedly de creased in the absence of CHMP5 (Fig. 10 B) , suggesting that CHMP5 mediates the interaction between USP15 and VCP/ p97. Previous studies have shown that VCP/p97 and its cofac tors interact with ubiquitinated client proteins and facilitate their degradation in proteasome (Koegl et al., 1999; Dai and Li, 2001 ). We therefore examined the effect of CHMP5 and USP15 on ubiquitination levels of VCP/p97 client proteins using a ubiquitination assay (Fig. 10 C) . Similar to our obser vation that IB ubiquitination was suppressed by CHMP5 working together with USP15 (Fig. 9 A) , overexpression of CHMP5 or USP15 downregulated the ubiquitination of pro teins physically associated with MycVCP/p97. Thus, CHMP5 is likely to dampen ubiquitination of VCP/p97client proteins via recruitment of USP15 to VCP/p97.
IBMPFD is associated with missense mutations in VCP/p97, the majority of which are located in the Nterminal and the D1 ATPase domains (Nalbandian et al., 2011) . Among these, R155H has been reported as the most common VCP mutation causing IBMPFD, and A232E is associated with severe clinical manifestations such as early onset of PDB and aggressive myop athy (Watts et al., 2004) . To examine if IBMPFDassociated were relatively normal in Chmp5 Ctsk osteoclasts (Fig. 8 F) and CHMP5 overexpression inhibited NFB activation by a constitutively active IKK, but not by RelA (unpublished data). Thus, these results suggest that CHMP5 functions down stream of the IKK complex and upstream of RelA.
CHMP5 and USP15 dampen RANK-mediated NF-B activation and osteoclast differentiation via IB stabilization To gain insight into the mechanism by which CHMP5 reg ulates NFB signaling, affinity purification-based mass spectrometry was performed to identify CHMP5binding proteins. Because CHMP5 interacts with other CHMP fam ily proteins as a component of the endosomal sorting com plexes required for transport (ESCRT) machinery (Shim et al., 2006; Tsang et al., 2006) , Flagtagged CHMP5WT and a CHMP5 mutant (D3) that fails to bind to other CHMP proteins were used to identify nonESCRT related proteins that are associated with the NFB pathway (unpublished data). As expected, ESCRT components, including VPS4B and CHMP1B, 2A, 2B, and 4B, were pulled down by CHMP5 WT but not the CHMP5D3 mutant. Ingenuity pathway analysis of the CHMP5binding proteins identified enrich ment of the protein ubiquitination pathway including the PDB genetic risk factor VCP/p97 (Yamanaka et al., 2012) and the deubiquitinating enzyme USP15 (Schweitzer et al., 2007; unpublished data) . Likewise, size exclusion chromatography showed that endogenous VCP/p97 and USP15 cofraction ated with a subset of CHMP5, RelA, IB, and the E3 ligase Trcp, which is consistent with a previous study showing that VCP/p97 binds ubiquitinated IB and Trcp (Fig. 8 A ; Dai et al., 1998; Li et al., 2014) . Furthermore, immunoprecip itation analysis confirmed that both endogenous and over expressed CHMP5 interact with USP15, VCP/p97, and Trcp in an osteoclast line and HEK293 cells, respectively ( Fig. 8 H  and unpublished data) . Thus, in osteoclasts, CHMP5 is a com ponent of the 550kD protein complex containing a subset of NFB RelA/IB and binds proteins involved in the regu lation of ubiquitinmediated proteasomal degradation, in cluding VCP/p97, USP15, and Trcp (Fig. 8 I) .
Given that CHMP5 binds the RelA-IB complex alongside USP15, VCP/p97, and Trcp, we hypothesized that CHMP5 may regulate NFB signaling via modulating ubiquitination of IB. An in vitro ubiquitination assay re vealed that IB ubiquitination was markedly inhibited by overexpression of CHMP5 or USP15 (Fig. 9 A) , which is ac companied with pulsechase labeling experiments showing that IB stability was increased by overexpression of CHMP5 or USP15 (Fig. 9, B and C) . Accordingly, the ability of RANKL to induce IB degradation was enhanced in the absence of CHMP5 or USP15 (Fig. 9, D and E) . Thus, CHMP5 and USP15 appear to stabilize IB in osteoclasts via suppression of ubiquitinationmediated proteasomal degradation. Given in vitro ubiquitination and deubiquitination assays that either SCF Trcp mediated ubiquitination of IB or ubiquitinated IB levels were not affected by addition of recombinant (D and E) RAW264.7 cells expressing control vector, Chmp5, or Usp15 shRNA were stimulated with 25 ng/ml of RANKL at different time points, and immunoblotted with the indicated antibodies (D). IB degradation was quantified using ImageJ and normalized to Hsp90 expression (E). (F and G) RAW264.7 cells expressing control vector or Usp15 shRNA were transfected with Chmp5 along with PBII-luc and Renilla (F). Alternatively, RAW264.7 cells were transfected with Usp15 in a dose-dependent manner along with PBII-luc and Renilla (G). Luciferase activity was measured and normalized to Renilla. *, P < 0.05; **, P < 0.01; ***, P < 0.0001 by a Bonferroni-corrected two-tailed Student's t test. (H) RAW264.7 cells expressing control vector or Usp15 shRNA were cultured in the presence of M-CSF and different concentrations of RANKL. TRAP staining was performed after 6 d. (I) WT BMMs were treated with vehicle or NF-B inhibitor for 1 h before RANKL stimulation. After 48 h of stimulation with RANKL, Chmp5 and Usp15 expression was analyzed by RT-PCR. ***, P < 0.0001 by a Bonferroni-corrected two-tailed Student's t test. Data in A-I represent n = 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bar: (H) 60 µm.
VCP/p97 mutations alter the binding affinity of VCP/p97 to CHMP5 or USP15, immunoprecipitation analysis was per formed with Myctagged VCP/p97 R155H and A232E con structs (Fig. 10, D and E) . Both VCP/p97 R155H and A232E displayed markedly decreased binding to CHMP5 and USP15. Similarly, whereas CHMP5 or USP15 can suppress the ubiq uitination of the client proteins associated with VCP/p97 WT, VCP/p97R155H, and VCP/p97A232E were refractory , and 24 h later, luciferase activity was measured and normalized to Renilla. **, P < 0.01 by a Bonferroni-corrected two-tailed Student's t test. Data in A-G represent n = 2 independent experiments. **, P < 0.01.
demonstrates that CHMP5 not only suppresses osteoclast dif ferentiation, but it also suppresses a broad transcriptional pro gram driving the expression of several osteoclast/osteoblast coupling factors. Among these coupling factors whose ex pression is regulated by CHMP5, the EphrinB2-EphB4 path way is particularly important, as it is necessary for the enhanced coupling activity of CHMP5deficient osteoclasts. However, the observation that several known osteoclast/osteoblast cou pling factors are regulated by CHMP5 indicates that addi tional pathways also contribute to this phenotype. Thus, by acting as a rheostat to tune RANK signaling in osteoclasts, CHMP5 in turn regulates systemic coupling of osteoclast and osteoblast activity.
Our previous study of mice with germline deletion of Chmp5 indicated the importance of CHMP5 function in late endosomal trafficking to lysosomes and in TGF signaling via regulating the lysosomal degradation of TGF receptors (Shim et al., 2006) . However, lysosomal biogenesis and endo somal structures are largely intact in Chmp5 Ctsk osteoclasts and TGF receptor levels and TGFinduced SMAD activation were unaltered in the absence of CHMP5 (unpublished data). This may be due to Ctskcre deleting Chmp5 after lysosomal biogenesis is complete in osteoclasts, or the specialization of endosomal/lysosomal structures in osteoclasts may necessitate the use of different pathways for their biogenesis. Additionally, we found that distinct domains mediate the interactions of CHMP5 with the endocytic and NFB pathways, implying that functions of CHMP5 in regulating NFB activity are biochemically distinct from its role in lysosomal biogenesis in osteoclasts. However, further studies will be required to deter mine if the functions of CHMP5 to regulate endocytosis and NFB pathway are linked.
The spectrum of human PDB and related monogenic forms of PDB encompass a wide range of phenotypic varia tion (Daroszewska and Ralston, 2006) . In this respect, the phenotype of Chmp5 Ctsk mice fits clearly within this spec trum, as the combination of periosteal hyperdynamic bone deposition, exaggerated bone remodeling coupled with in creased activities of osteoclasts and osteoblasts, bone expan sion, and osteoclasts displaying increased numbers of nuclei are pathognomonic for Paget'sspectrum disorders. Although sporadic PDB displays a greatly increased relative risk of os teosarcoma formation (Hansen et al., 2006) , no osteosarcomas were observed over the course of this study, and the early onset and polyostotic nature of the Chmp5 Ctsk bone pheno type is markedly different from classical PDB. Some PBD pa tients have been observed to display marrow fibrosis (Murrin and Harrison, 2004) , and this is not observed in Chmp5 Ctsk mice. Similarly, the vascular calcifications associated with JPD are not observed in Chmp5 Ctsk mice (Saki et al., 2013; Whyte et al., 2014) . However, further studies will be required to de termine the reasons for these differences. Lastly, it is possible that environmental factors are needed for full penetrance of all aspects of PDB phenotypes, as environmental factors which are acknowledged to be especially important for the patho genesis of PDB (Roodman, 2010) . to this effect (Fig. 10 F) . Thus, the R155H and A232E muta tions disrupt the physical and functional engagement of VCP/ p97 with CHMP5 and USP15. Consistent with this engage ment with CHMP5 and USP15, expression of VCP/p97WT but not VCP/p97R155H or VCP/p97A232E inhibited RANKmediated NFB activation (Fig. 10 G) , and addition of USP15 promoted a further decrease in the presence of VCP/p97WT but not VCP/p97R155H or VCP/p97 A232E (Fig. 10 G) . Thus, the IBMPFDassociated VCP/p97 mutations that disrupt engagement with CHMP5 and USP15 also influence the ability of VCP/97 to regulate the activation of NFB by RANK.
DISCUSSION
Our data reveal that CHMP5 is a key dampener of bone re modeling, preventing the development of a high turnover PDBlike state. CHMP5 mobilizes USP15 to deubiquitinate and stabilize IB, inhibiting ubiquitindependent protea somal degradation. This dampens RANKmediated activa tion of NFB in osteoclasts, in turn increasing the threshold of stimulation required for osteoclast differentiation and osteoclastmediated bone resorption. Intriguingly, CHMP5 and USP15 expression are both upregulated by RANKL, sug gesting that they may function in concert as a negative feed back mechanism to suppress NFB activity (Fig. 9 I) .
The rescue of the Chmp5 Ctsk bone phenotype by Rank haploinsufficiency demonstrates that exaggerated bone remod eling observed in vivo is directly attributable to the enhanced sensitivity to RANK stimulation observed in osteoclasts in vitro, though this result does not exclude that alterations in other pathways may also contribute to the phenotype ob served. Notably, Rank heterozygous mice do not display de tectable alterations in basal osteoclast numbers or activity (Dougall et al., 1999) . Thus, the ability of CHMP5 deletion to increase the sensitivity of osteoclasts to RANK stimulation in vitro is supported by the observation that Chmp5 Ctsk mice also display an increased sensitivity to reductions in Rank gene dosage in vivo. This conclusion is also reinforced by the observation that OPGFc, which directly inhibits RANK activation, is highly effective in rescue of the Chmp5 Ctsk bone phenotype. Unlike OPGFc treatment, Chmp5 Ctsk mice treated with bisphosphonates, which suppress osteoclast resorptive activity without directly affecting activation of RANK, still display bone expansion as a result of incomplete blockade of osteoblast activity. Through comparison of these attempts to reverse the Chmp5 Ctsk bone phenotype, we con clude that the osteoclast/osteoblast coupling in Chmp5 Ctsk mice is RANKdependent but is largely independent of os teoclast resorptive activity. Thus, coupling factors relevant to this model are likely to be directly produced by osteoclasts as opposed to being growth factors liberated from the bone ma trix during osteoclastmediated bone resorption. Consistent with this model, Chmp5 Ctsk osteoclasts display an enhanced ability to promote osteoblast activity in a coculture system in vitro. Likewise, transcriptome analysis of Chmp5 Ctsk osteoclasts neomycin and validated by Southern blotting. Subsequently, Cre recombinase expressing construct was transfected into the validated neomycinresistant clones and further selected to delete the PGKNEO cassette. Mice bearing the targeted allele were generated by blastocyst injection and backcrossed with C57BL/8 mice up to F8 generation.
Chmp5 Ctsk mice were generated by intercrossing Chmp5 fl/+ ;Cathepsin KCre breeders with Chmp5 fl/fl mice. Cathepsin Kcre mice were a gift from S. Kato (University of Tokyo, Tokyo, Japan). Chmp5 Ctsk /Rank het mice were generated by intercrossing Chmp5 fl/+ ;Rank fl/+ ;Cathepsin KCre mice with Chmp5 fl/fl ;Rank fl/+ breeders. All mice were on a C57BL/6 background. All animals were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the Weill Cornell Medical College sub committee on animal care (IACUC).
Cell culture, osteoclast, and osteoblast differentiation. Primary BMMs and RAW264.7 cells (American Type Culture Collection) were cultured in minimum essential medium (CellGro) supplemented with 10% FBS (Hy clone), 1% penicillin/streptomycin (Invitrogen), and 2 mM lglutamine (Invitrogen) in 5% CO 2 at 37°C. Primary calvarial osteoblasts (COBs) and BMderived stromal cell (BMSCs) were cultured in MEM (MEM; Invitrogen) containing 10% FBS, 1% penicillin/streptomycin, 2 mM lglutamine, 1% Hepes, and 1% nonessential amino acids. For osteoblast differentiation, the cells were cultured under basal medium containing glycerophosphate and ascorbic acid.
For osteoclast differentiation analysis, the femur and tibia were carefully dissected from 6wkold male Chmp5 fl/fl and Chmp5 Ctsk mice, and BM cells collected by flushing were plated overnight in -MEM plus 10% FBS. Non adherent cells were collected and seeded on a 100mm dish with mMCSF (30 ng/ml, R&D Systems). After 48 h, nonadherent cells were discarded and adherent cells were used as BMMs. BMMs were detached from the 100mm dish using Detachin (Genlantis). For the osteoclastogenesis, RAW264.7 (2.6 × 10 4 cells/cm 2 ) cells and BMMs (5.2 × 10 4 cells/cm 2 ) were cultured for 6 d in -MEM containing 5 ng/ml mRANKL (R&D Systems) or 20 ng/ml mRANKL and 40 ng/ml mMCSF, respectively. Alternatively, cells were plated on the bovine cortical bone slices (boneslices.com) and cultured with 20 ng/ml mRANKL and 40 ng/ml mMCSF. The number and area of the resorptive pits on the bone slice were counted and the amount of CTX lib erated from the bone slice to medium was measured by an ELISA kit (IDS) to assess bone resorption activity.
Osteoblast culture with osteoclast-conditioned medium. The condi tioned medium of Chmp5 fl/fl and Chmp5 Ctsk osteoclasts was harvested as de scribed previously. (Matsuoka et al., 2014) In brief, after 1 or 2 d culture with MEM medium containing 10% FBS, mRANKL (20 ng/ml), and mMCSF (40 ng/ml), Chmp5 fl/fl and Chmp5 Ctsk BMMs were cultured in the conditioned medium (CM) for 1 or 2 d and CM was harvested. Each CM was concentrated using the Amicon Ultra15 Filter Unit (10K; EMD Millipore). Coculture of osteoblasts with Chmp5 fl/fl and Chmp5 Ctsk osteoclasts was performed in the presence of various concentrations of mouseFc or mouse EphB4Fc (R&D Systems). After 12-18 d of culture, osteoblasts were stained with alizarin red and mineralization activity was measured by colorimetric analysis.
Histology, immunohistochemistry, and in situ hybridization. For histological analysis, hindlimbs were dissected from 6 or 12wkold male mice, fixed in 10% neutral buffered formalin for 24-48 h, and decalcified by daily changes of 15% tetrasodium EDTA for 2 wk. Tissues were dehydrated by passage through an ethanol series, cleared twice in xylene, embedded in paraffin, and sectioned at 7 µm thickness along the coronal plate from anterior to posterior. Decalcified femoral sections were stained with hematoxylin and eosin (H&E), Safranin O, and tartrateresistant acid phosphatase (TRAP).
For in situ hybridization, DIGlabeled probes were prepared to detect type I collagen (Col1) and osteocalcin (Ocn) mRNA expression using the DIGlabeling kit (Roche) according to the manufacturer's instructions. Par affin sections were dewaxed and quenched with endogenous peroxidase, and Given that variants in CHMP5 gene have yet to be iden tified in human patients with a Paget's spectrum disorder, we instead considered whether CHMP5 displays a functional interaction with other known genes implicated in a Paget's spectrum disorder. As variants in VCP/p97 gene cause the Paget'srelated disorder IBMPFD, and VCP/p97 has been implicated in regulation of IB, the relationship between CHMP5 and VCP/p97 was studied, demonstrating that CHMP5 serves as an adaptor to recruit the deubiquitinating enzyme USP15 to the VCP/p97 complex. This recruitment then leads to USP15mediated deubiquination of VCP/p97 client pro teins, likely salvaging them from proteasomal degradation. Ac cordingly, mutations in VCP/p97 that cause IBMPFD (R155H and A232E) disrupt both the physical and functional inter action with CHMP5 and USP15. Collectively with the PDB like skeletal phenotype of Chmp5 Ctsk mice, this indicates that CHMP5 cooperates with VCP/p97 to regulate RANK signal ing and that disruption of this functional interaction may be a key factor in the development of some Paget's spectrum dis orders. This also raises the possibility that VCP/p97 serves an important function to select the substrates targeted by the CHMP5-USP15 complex for deubiquitination.
The exuberant bone formation and expansion seen in Chmp5 Ctsk mice demonstrates the importance of CHMP5 for the regulation of bone turnover rates. As, to our knowledge, Chmp5 Ctsk mice represent one of the most severe mouse models of high turnover metabolic bone disease yet reported, we be lieve that they may offer an opportunity to identify osteoclast/ osteoblast coupling factors with anabolic activity, which may ultimately have utility for the treatment of osteoporosis. Addi tionally, the early onset, high severity, and complete penetrance displayed by this model may make this an attractive preclinical model to validate treatment for Paget'sspectrum disorders.
MATERIALS AND METHODS

Materials.
Mouse MCSF and mouse RANKL were purchased from R&D Systems. Antibodies to Chmp5 (Santa Cruz Biotechnology, Inc.), Hsp90/ (Santa Cruz Biotechnology, Inc.), IB (Santa Cruz Biotechnology, Inc.), Ubiquitin (Santa Cruz Biotechnology, Inc.), Trcp/HOS (Santa Cruz Bio technology, Inc.), NFB/p50 (Santa Cruz Biotechnology, Inc.), antiHA HRP conjugated antibody (Santa Cruz Biotechnology, Inc.), p65/RelA (Enzo Life Sciences), NFB/p100 (Cell Signaling Technology), Vcp/p97 (Cell Sig naling Technology), Flag (SigmaAldrich), GFP (Clontec), GAPDH (Affinity Bioreagents), Usp15 (Bethyl Laboratories), Nfatc1 (BioLegend), phospho IKK/ (Cell Signaling Technology), BiphosphoSyk (Y525/526; Abgent), TGF receptor, type 1 (EMD Millipore), phosphoSrc Family (Tyr416; Cell Signaling Technology), and Cathepsin K (Biovision) were used for immuno blotting. AntiHA agaroseconjugated antibody (Santa Cruz Biotechnology, Inc.) and anti-cMyc HRPconjugated antibody (Santa Cruz Biotechnology, Inc.), and antiHA HRP-conjugated antibody were used for immunoprecipi tation. NFB inhibitor Bay 11-7035 and active Rac1 detection kit were pur chased from Santa Cruz Biotechnology, Inc. and Cell Signaling Technology, respectively. For recombinant proteins, GSTNFB p65 and GSTIB were purchased from Enzo Life Sciences, and GSTCHMP5 and GSTp97/VCP were purchased from Novus Biologicals. The recombinant active SCFSkp2 protein complex and activated IB were purchased from EMD Millipore.
Mice. To generate Chmp5 floxed mice, exon 4 and 5 flanked by a 5 loxP site and a 3 loxPPGKNEOloxP cassette was cloned into the pEasyflox vector and the ES clones with homologous recombination were selected by prepared as described. After ligation of Illumina PE adaptors, cDNA was separated by electrophoresis through agarose gels and fragments with a size of 300-350 base pairs were excised for analysis. 50 bases, pairend read se quencing was performed on the Illumina HiSeq2000, which yielded 74 × 10 6 to 92 × 10 6 pairedend raw reads per sample. Those reads were aligned to the mouse genome (Mus musculus UCSC mm10) using with TopHat soft ware (version 2.0.10). Differentially expressed genes were presented using hypergeometric calculation implemented in the DESeq Bioconductor pack age in R statistical language.
Gene sets from the Broad Institute Molecular Signatures Database and a modified gene set (Table S2) were used, and multiple lists of enriched gene sets were generated using the GSEA algorithm as previously described. En richment for upregulation or downregulation in Chmp5 Ctsk RNAs was as sessed against a gene list preranked for log 2 ratio of expression from Chmp5 Ctsk RNAs to expression from Chmp5 fl/fl RNAs.
Immunoprecipitation, immunoblotting, immunofluorescence, and pulse-chase analysis. HEK293T cells were transfected with the indicated DNA constructs using Effectene reagents (QIAGEN), and then lysed in TNT lysis buffer (10 mM Tris, 50 mM NaCl, 5 mM EDTA, 2 mM NaF, 30 mM sodium pyrophosphate, 100 mM Na 3 VO 4 , 0.5 mM PMSF, 1 µg/ml leupeptin, 5 µg/ml aprotinin, and 1% Triton X100). Proteins from cell lysates were immunoprecipitated with Flag, HA, or Mycconjugated aga rose, and the immunoprecipitates were subjected to SDSPAGE and transferred to ImmunobilonP membranes (EMD Millipore). Alternatively, Chmp5 fl/fl and Chmp5 Ctsk BMMs were cultured in the presence of MCSF and RANKL, and after 3-4 d total cell lysates were immunoblotted with antibodies specific to IB, SRC, phosphoSRC, phosphoSYK, and CHMP5. Immunoblotting with antibodies specific to Gapdh or Hsp90/ was used as a loading control. For actin ring staining, cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X100, washed in PBS, and stained with Alexa Fluor 488phalloidin (Life Technologies).
HEK293 cells transfected with the indicated DNA constructs were incubated under starvation conditions (3% dFBS, glutamine and Hepes in Cys/Met free DMEM) for 3 h. Subsequently, cells were incubated in label ing medium containing [ 35 S]methionine for 1 h, and cultured in chase me dium (5% FBS, +Cys, +Met, glutamine, and Hepes in DMEM) for various durations. Cells were then lysed, immunoprecipitated with antiFlag (M2) antibody-conjugated agarose, and subjected to SDSPAGE. Labeled pro teins were visualized with autoradiography and were quantified using ImageJ (National Institutes of Health).
Luciferase reporter assay and DNA binding assay. In brief, HEK293 cells or RAW264.7 cells were transfected with a NFB-responsive (PBII luc) or AP1responsive reporter gene (2xAP1luc) along with Renilla (Pro mega). 24 h after transfection, the cells were stimulated with 50 ng/ml RANKL for 48 h and lysed with 1× passive lysis buffer (Promega). Lucifer ase activity was measured using the dualluciferase reporter assay kit (Pro mega). Relative luciferase activity was normalized to Renilla.
NFB DNA binding assays were performed as described in the manu facturer's instructions for the NFB p65 enzyme linked immunosorbent assay (ELISA) kit (Enzo Life Sciences). In brief, total cell lysates were incubated for 30 min at room temperature on the p65 consensus oligonucleotide coated plates. The active form of p65 bound to consensus oligonucleotides were sequentially incubated with antip65 antibody and HRPconjugated secondary antibody. The oligonucleotidebound active p65 were incubated with a chemiluminescent substrate, and DNA binding affinity was measured by a luminometer.
Ubiquitination assay. HEK293 cells were transfected with Hisubiquitin, MycTrcp, and FlagIB, along with control vector, CHMP5, or USP15. After 24h transfection, the cells were treated with 10 mM MG132 (EMD Millipore) for 6 h, lysed and sonicated in the denaturation buffer (8 M Urea, 50 mM Tris, pH 8.0, 1.0% Triton X100, 10 mM Imidazol, and 10 mM mercaptoethanol), and immunoprecipitated with NiNTA beads. then hybridized with the probes. DIGlabeled probe was then detected by immunostaining with anti-DIGPOD and streptavidinHRP.
For immunohistochemistry, paraffin tissue sections were dewaxed and blocked with 3% goat serum, 1% BSA, 0.1% Triton X100 in PBS for 1 h at room temperature. Sections were incubated with antibodies specific to CHMP5 (Santa Cruz Biotechnology, Inc.; clone H7), PECAM1 (CD31, Santa Cruz Biotechnology, Inc.; clone M6), VEGF (EMD Millipore, 07-1420), and collagen type I (Rockland) at 4°C overnight, treated with TSAbiotin (Perkin Elmer), and streptavidinHRP, as per manufacturer's instructions, and then visualized with 2,2diaminobenzidine tetrahydrochloride.
CT analysis, bone histomorphometry, and skeletal preparation. For CT analysis, a Scanco Medical CT 35 system with an isotropic voxel size of 7 µm was used to image the distal femur. Scans were conducted in 70% ethanol and used an xray tube potential of 55 kVp, an xray intensity of 0.145 mA, and an integration time of 600 ms. For trabecular bone analysis of the distal femur, a upper 2.1mm region beginning 280 µm proximal to the growth plate was contoured. For cortical bone analysis of femur and tibia, a midshaft region of 0.6 mm in length was used. Trabecular and cortical bones were thresholded at 211 and 350 per mgHA/cm 3 , respectively. CT CT scans of skulls, vertebrae and feet were performed using isotropic voxel sizes of 12 and 20 µm. 3D images were obtained from contoured 2D images by methods based on distance transformation of the binarized images. All images presented are representative of the respective genotypes.
For the bone histomorphometry, 20 mg/kg calcein (SigmaAldrich) and 30 mg/kg demeclocycline (SigmaAldrich) dissolved in 2% sodium bicar bonate solution were injected subcutaneously with 4d interval at day 6 and day 2 before the sacrifice. Undecalcified tibia samples were fixed in 4% PFA embedded in plastic resin for bone sections. The sections were stained with von Kossa and TRAP, and numbers and activities of osteoblasts and osteo clasts were quantified using the Bioquant Osteo Image Analysis System. Skeletons were also prepared for analysis of gross morphology using the method of McLeod. In brief, mice were sacrificed, skinned, eviscerated, and fixed in 95% ethanol for a day. Next, skeletons were stained by Alizarin Red S and Alcian Blue solutions and sequentially cleared in 1% potassium hydroxide.
Complete blood count test. Blood was collected from 12wkold male Chmp5 fl/fl and Chmp5 Ctsk mice (n = 5 mice/group) by cardiac puncture immediately after sacrifice. All parameters for complete blood counts were calculated by a Hemavet 950 analyzer (Drew Scientific) according to the manufacturer's instructions.
Antiresorptive treatment. PBS, 2.5 mg/kg alendronate sodium trihydrate (SigmaAldrich), 100 µg/kg zolendronic acid monohydrate (SigmaAldrich), or rat 3 mg/kg OPG-Fc (Amgen Inc.) was intraperitoneally injected weekly to Chmp5 fl/fl and Chmp5 Ctsk male mice from 2-5 wk of age, and the mice were all sacrificed at 6 wk of age and used for skeletal analysis.
Bone RNA isolation and RT-PCR analysis. Bone RNA was prepared as previously described. In brief, tibias were isolated from 6wkold male Chmp5 fl/fl and Chmp5 Ctsk mice, and cleaned of surrounding soft tissue, and BM cells were removed by flushing with PBS. Immediately, bones were transferred to the prechilled tubes containing QIAzol lysis reagent (QIA GEN) and homogenized using a Polytron (Kinematic PT 2100, 7 mm tip) under a rack surrounded by liquid nitrogen. cDNA was reverse transcribed using random primers and MultiScribe reverse transcription (Applied Biosys tems) and used in realtime PCR with a SYBR Green PCR Master Mix kit (Applied Biosystems). The specific primer pairs are shown in Table S1 .
RNA-sequencing analysis and gene set enrichment analysis (GSEA).
BMMs were isolated from male Chmp5 fl/fl and Chmp5 Ctsk mice (n = 3 mice per group) and cultured in the presence of MCSF and RANKL. Total RNAs were isolated from osteoclasts at day 3 of culture using QIAzol lysis reagent (QIAGEN). Quality control test of the RNAs were conducted using the Agilent Bioanalyzer 2100 and libraries for Illumina sequencing were Biomarkers of bone turnover. Blood was collected from 6wkold male Chmp5 fl/fl and Chmp5 Ctsk mice (n = 5/group) by cardiac puncture and di vided into two groups. Serum was separated using serum separator tubes and serum levels of ALP (CloudClone), P1NP (IDS), and CTX (IDS) were measured using each ELISA kits as per the manufacturer's instructions.
Statistical analysis.
Data are shown as the mean ± SEM. Sample sizes were calculated on the assumption that a 30% difference in the parameters measured would be considered biologically significant with an estimate of sigma of 10-20% of the expected mean.  and  were set to the standard values of 0.05 and 0.8, respectively. No animals or samples were excluded from analysis. In Fig. 4 (f and g), mice were randomized to treatment groups (aldendronate, zolendro nate, OPGFc, or PBS). µCT analysis was performed in a blinded fashion. We first performed the ShapiroWilk normality test for checking normal dis tributions of the groups. If normality tests passed, twotailed, unpaired Stu dent's t tests were used for the comparisons between two groups; if normality tests failed, MannWhitney tests were used for the comparisons between two groups. For the comparisons of three or four groups, we used oneway ANOVA if normality tests passed, followed by Tukey`s multiple comparison test for all pairs of groups. If normality tests failed, KruskalWallis test was per formed and followed by Dunn`s multiple comparison test. The GraphPad PRISM software (v6.0a) was used for statistical analysis. P < 0.05 was consid ered statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Table S1 shows the specific primer pairs used in RTPCR analysis of bone and cultured osteoclast RNAs. Table S2 shows a gene set related to the osteoclast differentiation and fusion modified from Broad Institute Molecular Signatures Database. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20150407/DC1.
Online supplemental material.
